Quốc gia: Nam Phi
Ngôn ngữ: Tiếng Anh
Nguồn: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
RAMPIL 1,25 MG CAPSULE RAMPIL 2,5 MG CAPSULE RAMPIL 5 MG CAPSULE RAMPIL 10 MG CAPSULE SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): RAMPIL 1,25 MG CAPSULE RAMPIL 2,5 MG CAPSULE RAMPIL 5 MG CAPSULE RAMPIL 10 MG CAPSULE COMPOSITION RAMPIL 1,25 mg - Each capsule contains 1,25 mg of ramipril . RAMPIL 2,5 mg - Each capsule contains 2,5 mg of ramipril. RAMPIL 5 mg - Each capsule contains 5 mg of ramipril. RAMPIL 10 mg - Each capsule contains 10 mg of ramipril. PHARMACOLOGICAL CLASSIFICATION A 7.1.3 Other hypotensives PHARMACOLOGICAL ACTION Ramipril inhibits angiotensin I-converting enzyme (ACE) activity. It inhibits the conversion of the relatively inactive angiotensin I to the active angiotensin II. Angiotensin II is a potent vasocontrictor and stimulates the release of aldosterone. Decreased angiotensin II levels result in a decrease in vasopressor activity and reduction in aldosterone secretion, which may result in small increases in serum potassium. It is also thought that ACE inhibition may inhibit degradation of bradykinin, leading to increased bradykinin levels. Pharmacokinetics: The extent of absorption after oral administration is 60% with wide variability between patients. The plasma half-life is increased in renal impairment. The time to achieve peak serum concentration is within 1 hour. Ramipril is renally eliminated and excreted 100% unchanged in the urine. INDICATIONS RAMPIL capsules are indicated for the following: • Mild to moderate hypertension. • Cardiac failure following myocardial infarction. • To reduce proteinuria and the decline in glomerular filtration rate in patients with diabetic nephropathy and hypertension. • To reduce the risk of myocardial infarction, stroke or cardiovascular death and to reduce the ne Đọc toàn bộ tài liệu